CTC
VTVT icon

Central Trust Company’s vTv Therapeutics VTVT Stock Holding History

Central Trust Company’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5
Closed -$118 – 1458
2024
Q1 		$118 Buy
+5
New +$64 ﹤0.01% 1364

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCMC
Planning Capital Management Corporation Paoli, Pennsylvania $151M AUM 30.62% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
SFCL
Strengthening Families & Communities LLC Boston, Massachusetts $401M AUM 33.17% 1-Year Est. Return

Central Trust Company's VTVT Position: Q2 2024 in Review

Central Trust Company sold out of vTv Therapeutics (VTVT) in Q2 2024, closing a stake of 5 shares — an estimated $118 sold.

Central Trust Company first reported a position in VTVT in Q1 2024 and held it in 1 quarter. The position peaked at $118 in Q1 2024. 19 funds tracked by Wall St. Rank hold VTVT as of Q2 2024.

  • Central Trust Company reported no remaining vTv Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Central Trust Company sold 5 vTv Therapeutics shares in Q2 2024, an estimated $118.
  • Central Trust Company first reported a position in vTv Therapeutics in Q1 2024 and held it in 1 quarter.
  • Central Trust Company's vTv Therapeutics position peaked at $118 in Q1 2024.
  • 19 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2024.

Based on Central Trust Company's 13F filing for Q2 2024, filed 5 Aug 2024.